SUPPLEMENTARY MATERIAL

New flavonoid glycosides from seeds of Baccharoides anthelmintica

Yi Liu^{a,b}, Wen-Qiong Wang^a, Tong-Chen^a and Li-jiang Xuan^{a*}

^a State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, People's Republic of China

^bUniversity of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, People's Republic of China

*Corresponding Author

Prof. Dr. Li-jiang Xuan, Tel/fax: +86 21 20231968. E-mail: ljxuan@simm.ac.cn

Abstract: *Baccharoides anthelmintica* is the most popular traditional Uighur medicines used for vitiligo. The chemical investigation of the seeds of *B. anthelmintica* led to the isolation of three new flavonoid glycosides (Vernosides A-C). Their structures were determined by comprehensive analysis of spectroscopic data including 1D and 2D NMR and HRMS data. Vernosides A-C were evaluated for their effects on tyrosinase activity, Vernoside B can enhance tyrosinase activity.

Key words: Baccharoides anthelmintica; vitiligo; flavonoid glycosides

List of content

Abbreviations

- Table S1. ¹H NMR (500 MHz) and ¹³C NMR (125 MHz) data for Compounds 1-3 ($\delta_{\rm H}$,
- $\delta_{\rm C}$ in ppm, *J* in Hz)
- Figure S1. Key COSY and HMBC correlations of compounds 1-3
- Figure S2. ¹H NMR spectrum of compound **1** in CD₃OD
- Figure S3. ¹³C NMR spectrum of compound **1** in CD₃OD
- Figure S4. ¹H-¹H COSY spectrum of compound **1** in CD₃OD
- Figure S5. HSQC spectrum of compound 1 in CD₃OD
- Figure S6. HMBC spectrum of compound **1** in CD₃OD
- Figure S7. ¹H NMR spectrum of compound **2** in CD₃OD
- Figure S8. ¹³C NMR spectrum of compound **2** in CD₃OD
- Figure S9. HSQC spectrum of compound 2 in CD₃OD
- Figure S10. HMBC spectrum of compound 2 in CD₃OD
- Figure S11. ¹H NMR spectrum of compound **3** in CD₃OD-CDCl₃(1:1)
- Figure S12. ¹³C NMR spectrum of compound **3** in CD₃OD-CDCl₃(1:1)
- Figure S13. HSQC spectrum of compound **3** in CD₃OD-CDCl₃(1:1)
- Figure S14. HMBC spectrum of compound **3** in CD₃OD-CDCl₃(1:1)
- Figure S15. Activation of tyrosinase activity by compound 2
- Figure S16. IR spectrum of compound 1
- Figure S17. HR-ESI-MS spectrum of compound 1
- Figure S18. IR spectrum of compound 2
- Figure S19. HR-ESI-MS spectrum of compound 2
- Figure S20. IR spectrum of compound 3
- Figure S21. HR-ESI-MS spectrum of compound 3

Abbreviations

HMBC: ¹H detected heteronuclear multiple-bond correlation

COSY: correlated spectroscopy

HSQC: ¹H detected heteronuclear single-quantum coherence

position	1^{a}		2^a		3^b	
	$\delta_{ m H}$	$\delta_{ m C}$	$\delta_{ m H}$	$\delta_{ m C}$	$\delta_{ m H}$	$\delta_{ m C}$
2	5.12 (dd, 10.5, 3.6)	74.3	5.08 (d, 12.3)	74.8	4.99 (d, 12.1)	74.2
3	2.08 (m), 2.06 (m)	39.8	2.25 (m) 1.99 (m)	36.7	2.25 (m) 1.96 (m)	35.5
4	4.68 (dd, 2.4, 2.2)	64.2	4.37 (dd, 5.3, 2.7)	72.1	4.22 (m)	73.3
5	7.13 (d, 8.5)	132.4	7.06 (d, 8.4)	132.8	7.05 (d, 8.4)	132.4
6	6.68 (dd, 8.5, 2.5)	110.3	6.65 (dd, 8.4, 2.4)	110.4	6.64 (dd, 8.4, 2.5)	109.8
7		157.1		157.5		156.8
8	6.58 (d, 2.5)	105.4	6.62 (d, 2.4)	105.2	6.62 (d, 2.5)	105.0
9		159.8		160.2		159.5
10		119.1		117.0		115.8
11			3.63 (m) 3.69 (m)	64.6	3.41 (s)	56.1
12			1.24 (t, 7.0)	15.9		
1′		133.4		133.5		133.6
2'	7.25 (d, 8.5)	128.8	7.25 (d, 8.5)	128.8	6.87 (d, 1.9)	114.4
3'	6.80 (d, 8.5)	116.2	6.81 (d, 8.5)	116.2		145.7
4′		158.3		158.5		156.9
5'	6.80 (d, 8.5)	116.2	6.81 (d, 8.5)	116.2	6.80 (d, 8.1)	115.9
6'	7.25 (d, 8.5)	128.8	7.25 (d, 8.5)	128.8	6.75 (dd, 1.9, 8.1)	118.8
1″	5.02 (d, 5.6)	101.8	4.93 (d, 7.3)	102.0	4.91 (d, 6.5)	101.4
2″	3.78 (m)	74.8	3.49 (m)	74.8	3.52 (m)	74.0
3″	3.51 (m)	77.8	3.41 (m)	77.8	3.40 (m)	77.2
4″	3.43 (m)	72.0	3.40 (m)	72.0	3.42 (m)	74.2
5″	3.48 (m)	75.4	3.83 (m)	75.6	3.79 (m)	74.9
6″	4.64 (m), 4.33 (m)	65.0	4.72 (m) 4.35 (m)	65.6	4.71 (d, 12.3) 4.36 (dd, 11.8, 7.6)	65.2
1‴		121.8		131.1		130.3
2‴	7.86 (d, 8.7)	132.9	7.99 (d, 7.5)	130.6	7.97 (d, 7.8)	130.2
3‴	6.76 (d, 8.7)	116.3	7.28 (t, 7.5)	129.6	7.25 (t, 7.8)	129.1
4‴		163.9	7.48 (t, 7.5)	134.2	7.47 (t, 7.4)	133.9
5‴	6.76 (d, 8.7)	116.3	7.28 (t, 7.5)	129.6	7.25 (t, 7.8)	129.1
6‴	7.86 (d, 8.7)	132.9	7.99 (d, 7.5)	130.6	7.97 (d, 7.8)	130.2
7‴		168.1		167.9		167.7
^a Recorde	ed in CD ₃ OD. ^b Record	ed in CD ₃	OD-CDCl ₃ (1:1).			

Table S1. ¹H NMR (500 MHz) and ¹³C NMR (125 MHz) data for Compounds 1-3 ($\delta_{\rm H}$, $\delta_{\rm C}$ in ppm, *J* in Hz)



Figure S1. Key COSY and HMBC correlations of compounds 1-3







Figure S4. 1 H- 1 H COSY spectrum of compound **1** in CD₃OD

Figure S5. HSQC spectrum of compound 1 in CD₃OD



-10 -20 -30 -40 -50 -60 0 . th -70 0 . .0 . . -80 -90 (ppm) -100 30... -110 1 120 -130 (9 19 0 0 . 8 -140 150 . ! 8_ 0 **8**6'' 160 00 (8 8 -170 180 190 -200 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 f2 (ppm) 1.5 0.5 0.0 1.0

Figure S6. HMBC spectrum of compound 1 in CD₃OD

Figure S7. ¹H NMR spectrum of compound 2 in CD₃OD





Figure S8. ¹³C NMR spectrum of compound **2** in CD₃OD



Figure S10. HMBC spectrum of compound 2 in CD₃OD

Figure S11. ¹H NMR spectrum of compound **3** in CD₃OD-CDCl₃(1:1)





Figure S12. ¹³C NMR spectrum of compound **3** in CD₃OD-CDCl₃(1:1)

4.0 3.5 3.0 2.5

5.0 4.5 f2 (ppm)

6.0 5.5

2.0 1.5 1.0 0.5

9.0 8.5 8.0 7.5 7.0 6.5

-150 -160 -170 -180 -190



Figure S14. HMBC spectrum of compound **3** in CD₃OD-CDCl₃(1:1)

Figure S15. Activation of tyrosinase activity by compound 2



Percent increase

Concentration (μM)





Figure S17. HR-ESI-MS spectrum of compound 1



User Spectra









--- End Of Report ---











--- End Of Report ---